JPMorgan analyst Christopher Neyor reiterated an Overweight rating on iTeos Therapeutics (NASDAQ: ITOS).The analyst comments "On the back of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE